Modulating IL-21-driven B cell responses in idiopathic inflammatory myopathies via inhibition of the JAK/STAT pathway
These findings highlight the B cell involvement in IIM, evidenced by altered peripheral B cell composition in active disease and the effective inhibition of essential B cell responses, including proliferation, differentiation, and (auto)antibody production, by tofacitinib in vitro. This positions the JAK/STAT pathway as a promising new therapeutic target to modulate B cell activity in IIM.
Authors
- Joost Raaphorst (ORCID: https://orcid.org/0000-0002-3658-2001)
- Ingrid E. Lundberg (ORCID: https://orcid.org/0000-0002-6068-9212)
- Louis Boon (ORCID: https://orcid.org/0000-0002-0937-9171)
- Sander W. Tas (ORCID: https://orcid.org/0000-0002-8940-1788)
- Giulia Frazzei (ORCID: https://orcid.org/0009-0005-3510-5632)
- Anneke J. van der Kooi (ORCID: https://orcid.org/0000-0002-5261-5512)
- Jan Piet van Hamburg (ORCID: https://orcid.org/0000-0002-6760-4648)
- Ana Merino-Vico
- Lisa Landman
- Merve Koçyiğit
- Ester M. van Leeuwen
Institutions
- Karolinska University Hospital (SE)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1186/s13075-025-03547-2
- Citations
- 2
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Amsterdam University Medical Centers
- Dutch Arthritis Association